当前位置:循环首页>正文

JUPITER试验:稳定型冠心病患者血清C-反应蛋白水平

Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective.

作者:国际循环网   日期:2010/12/6 16:23:40

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

BACKGROUND: The JUPITER trial has recently demonstrated an outstanding reduction of cardiovascular events by 20 mg rosuvastatin/day in subjects with high CRP who were apparently healthy at baseline.

    Saely CH, Rein P, Vonbank A, Drexel H.
Abstract
    BACKGROUND: The JUPITER trial has recently demonstrated an outstanding reduction of cardiovascular events by 20 mg rosuvastatin/day in subjects with high CRP who were apparently healthy at baseline. However, absence of atherosclerosis in JUPITER was based on the subjects’ history and not proven objectively.
    METHODS: To put the results of JUPITER in perspective, we evaluated serum CRP in a consecutive series of 703 statin-naïve Caucasian patients with angiographically proven stable CAD.
    RESULTS: From these stable CAD patients, only 69.2% met the ≥2.0 mg/l serum CRP inclusion criterion of the JUPITER trial. Median CRP [interquartile range] in our CAD patients was 3.3 [1.6-6.6] mg/l, which was significantly (p<0.001) lower than the median CRP in JUPITER (4.2 mg/l).
    CONCLUSIONS: Our results point to considerable subclinical atherosclerosis in the patients studied in JUPITER. The impressive results of that trial may not be generalizable to healthy populations all over the world.

 

版面编辑:沈会会  责任编辑:张衡


JUPITER稳定型冠心病C-反应蛋白

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530